Abatacept (cytotoxic T-lymphocyte–associated antigen 4–immunoglobulin fusion protein [CTLA-4–Ig]), a costimulatory inhibitor that targets CD80, has been used in CD80-accociated nephropathy (Yu et al., 2013; Trimarchi, 2015). Here, CD80 is linked to kidney disorder.